Xiaotian Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaotian Hu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Chen Chen
School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia
2 shared publications - Fang Yan
Department of Mathematics, Yunnan Normal University, Kunming 650500, P. R. China
2 shared publications - Huifen Zhai
Department of Respiratory Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China
2 shared publications - Shibo Sun
Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital, Kunming Medical University, Kunming, China
2 shared publications - Weimin Yang
School of Pharmaceutical Science & Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming 650500, China
2 shared publications Baomin Dong
1 shared publication
Latest Publications
- 16 June 2025
- Published by Elsevier in Journal of Asian Economics
- Vol. 100
Understanding the product structure of exporters: The role of intellectual property protection in export origins
- 16 June 2025
- Published by Elsevier in Journal of Asian Economics
- Vol. 100
Understanding the product structure of exporters: The role of intellectual property protection in export origins
- Open Access
- 9 February 2022
- Published by Elsevier in Economic Modelling
- Vol. 110
Do stronger intellectual property rights protections raise productivity within the context of trade liberalization? Evidence from China
- 9 February 2022
- Published by Elsevier in Economic Modelling
- Vol. 110
Open AccessDo stronger intellectual property rights protections raise productivity within the context of trade liberalization? Evidence from China
- Top Cited Papers
- 1 January 2022
- Published by Elsevier in International Review of Economics & Finance
- Vol. 77, 143-158
Intellectual property rights protection and export product quality: Evidence from China
- 1 January 2022
- Published by Elsevier in International Review of Economics & Finance
- Vol. 77, 143-158
Top Cited PapersIntellectual property rights protection and export product quality: Evidence from China
- Open Access
- 14 August 2019
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 15 (1) , 1-6
Sestrin2 is involved in asthma: a case–control study
Asthma is a chronic disease that seriously harms the health of patients. Oxidative stress is involved in asthma. As an oxidative stress-inducible protein, sestrin2 is elevated in oxidative stress-related diseases. We aimed to explore whether sestrin2 was involved in asthma. Seventy-six subjects (44 in the asthma group, 32 in the control group) were recruited in this study. Plasma sestrin2 levels, peak expiratory flow (PEF), forced expiratory volume in 1 s (FEV1) % predicted, forced vital capacity (FVC) % predicted and FEV1/FVC ratio were measured in controls and in asthmatics both during an exacerbation and when controlled after the exacerbation. The asthma group had a significant higher sestrin2 level than the control group (asthmatics during exacerbation, 1.75 ± 0.53 ng/mL vs. 1.32 ± 0.48 ng/mL, p < 0.001; asthmatics when controlled after the exacerbation, 1.56 ± 0.46 ng/mL vs. 1.32 ± 0.48 ng/mL, p = 0.021, respectively). In addition, sestrin2 was negatively correlated with FEV1% predicted and FEV1/FVC ratio in asthmatics during exacerbation (r = − 0.393, p = 0.008; r = − 0.379, p = 0.011; respectively). Moreover, negative correlations between sestrin2 and FEV1% predicted and FEV1/FVC ratio also existed in asthmatics when controlled after the exacerbation (r = − 0.543, p < 0.001; r = − 0.433, p = 0.003 respectively). More importantly, multiple linear regression analysis demonstrated that FEV1% predicted was independently associated with sestrin2 in asthmatics both during exacerbation and when controlled after the exacerbation. Sestrin2 is involved in asthma. Sestrin2 levels increase in asthmatics both during exacerbation and when controlled after the exacerbation. In addition, sestrin2 is independently associated with FEV1% predicted.
- 14 August 2019
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 15 (1) , 1-6
Open AccessSestrin2 is involved in asthma: a case–control study
Asthma is a chronic disease that seriously harms the health of patients. Oxidative stress is involved in asthma. As an oxidative stress-inducible protein, sestrin2 is elevated in oxidative stress-related diseases. We aimed to explore whether sestrin2 was involved in asthma. Seventy-six subjects (44 in the asthma group, 32 in the control group) were recruited in this study. Plasma sestrin2 levels, peak expiratory flow (PEF), forced expiratory volume in 1 s (FEV1) % predicted, forced vital capacity (FVC) % predicted and FEV1/FVC ratio were measured in controls and in asthmatics both during an exacerbation and when controlled after the exacerbation. The asthma group had a significant higher sestrin2 level than the control group (asthmatics during exacerbation, 1.75 ± 0.53 ng/mL vs. 1.32 ± 0.48 ng/mL, p < 0.001; asthmatics when controlled after the exacerbation, 1.56 ± 0.46 ng/mL vs. 1.32 ± 0.48 ng/mL, p = 0.021, respectively). In addition, sestrin2 was negatively correlated with FEV1% predicted and FEV1/FVC ratio in asthmatics during exacerbation (r = − 0.393, p = 0.008; r = − 0.379, p = 0.011; respectively). Moreover, negative correlations between sestrin2 and FEV1% predicted and FEV1/FVC ratio also existed in asthmatics when controlled after the exacerbation (r = − 0.543, p < 0.001; r = − 0.433, p = 0.003 respectively). More importantly, multiple linear regression analysis demonstrated that FEV1% predicted was independently associated with sestrin2 in asthmatics both during exacerbation and when controlled after the exacerbation. Sestrin2 is involved in asthma. Sestrin2 levels increase in asthmatics both during exacerbation and when controlled after the exacerbation. In addition, sestrin2 is independently associated with FEV1% predicted.
- Open Access
- 15 February 2019
- Published by Springer Nature in Lung
- Vol. 197 (2) , 123-129
Investigation of Urinary Sestrin2 in Patients with Obstructive Sleep Apnea
Background Obstructive sleep apnea (OSA) is a disease seriously threatening individual health, which results in serious complications such as hypertension and stroke. These complications are associated with oxidative stress triggered by intermittent hypoxia in OSA. Sestrin2 is a crucial factor involved in oxidative stress. The goal of this study was to investigate if a relationship exists between OSA and Sestrin2. Methods We prospectively enrolled 71 subjects, and 16 patients of them with severe OSA completed 4 weeks of nasal continuous positive airway pressure (nCPAP) therapy. We measured and compared the concentration of Sestrin2 in the urine of all subjects, as well as the changes between before and after nCPAP treatment. Additionally, the correlation between Sestrin2 and sleep parameters was analyzed, and the multiple linear regression analysis with stepwise selection was performed to explore the relationship between Sestrin2 and various factors. Results A total of 71 subjects were enrolled and divided into two groups: OSA group (n = 41), control group (n = 30). The level of urinary Sestrin2 in OSA patients was significantly higher than that of the control group, and increased with the severity of OSA, while it reduced after nCPAP treatment. Additionally, Sestrin2 was positively correlated with apnea/hypopnea index (AHI), oxygen desaturation index, oxygen saturation < 90% percentage of recording time spent (PRTS) and high-density lipoprotein (HDL), while negatively correlated with the lowest oxygen saturation. Importantly, Sestrin2 was independently associated with AHI, oxygen saturation < 90% PRTS and HDL. Conclusions Urinary Sestrin2 is involved in OSA, and is a paramount marker of OSA severity.
- 15 February 2019
- Published by Springer Nature in Lung
- Vol. 197 (2) , 123-129
Open AccessInvestigation of Urinary Sestrin2 in Patients with Obstructive Sleep Apnea
Background Obstructive sleep apnea (OSA) is a disease seriously threatening individual health, which results in serious complications such as hypertension and stroke. These complications are associated with oxidative stress triggered by intermittent hypoxia in OSA. Sestrin2 is a crucial factor involved in oxidative stress. The goal of this study was to investigate if a relationship exists between OSA and Sestrin2. Methods We prospectively enrolled 71 subjects, and 16 patients of them with severe OSA completed 4 weeks of nasal continuous positive airway pressure (nCPAP) therapy. We measured and compared the concentration of Sestrin2 in the urine of all subjects, as well as the changes between before and after nCPAP treatment. Additionally, the correlation between Sestrin2 and sleep parameters was analyzed, and the multiple linear regression analysis with stepwise selection was performed to explore the relationship between Sestrin2 and various factors. Results A total of 71 subjects were enrolled and divided into two groups: OSA group (n = 41), control group (n = 30). The level of urinary Sestrin2 in OSA patients was significantly higher than that of the control group, and increased with the severity of OSA, while it reduced after nCPAP treatment. Additionally, Sestrin2 was positively correlated with apnea/hypopnea index (AHI), oxygen desaturation index, oxygen saturation < 90% percentage of recording time spent (PRTS) and high-density lipoprotein (HDL), while negatively correlated with the lowest oxygen saturation. Importantly, Sestrin2 was independently associated with AHI, oxygen saturation < 90% PRTS and HDL. Conclusions Urinary Sestrin2 is involved in OSA, and is a paramount marker of OSA severity.